On Epstein, a throwback to keep in mind:
Jeffrey Epstein had a 'Frankenstein'-like plan to analyze human DNA in the US Virgin Islands, and it reportedly pulled in $200 million
Erin Brodwin Oct 4, 2019, 11:21 AM
Jeffrey Epstein received a valuable tax break on the basis of an outlandish business plan to study people's DNA on a Caribbean island and sell the resulting data to drug manufacturers.
The venture overseeing the project, called Southern Trust, pulled in $200 million in revenues, the New York Times reported on Friday…
The goal was to create a search engine capable of pinpointing genetic links to diseases like cancer, according to a 2012 transcript obtained by Business Insider through a public-records request. The transcript contains Epstein's testimony before the Virgin Islands Economic Development Authority, as part of an application he filed on the behalf of one of his companies, Southern Trust, for tax breaks.
"What Southern Trust will do will be basically organizing mathematical algorithms so that if I want to know what my predisposition is for cancer we can now have my genes specifically sequenced," Epstein said.
The science project had three main elements: First, a team of researchers would gather DNA from St. Thomas residents and use it to create catalog of population-level genetics data. Second, the team would design a search engine that would allow them to look for links to particular diseases. Finally, they would create a "virtual laboratory" to do experiments with computer models.
Gabriel Otte, the founder and CEO of cancer genetics startup Freenome, said Epstein's plan was far-fetched and simplistic. Two other knowledgeable sources consulted by Business Insider concurred.
"It's like he had conversations with 10 people who knew what they were doing and said, 'I'm going to create a company that does all of these things,'" Otte told Business Insider.
The idea of sequencing people's DNA, analyzing it, and selling the insights to drug companies is well-known to companies in the space, for example.
Last year, personal genetics company 23andMe signed a $300 million deal last year to sell de-identified batches of genetic data to drug giant GlaxoSmithKline; Calico, Google's life-extension spinoff, once teamed up with genealogy and DNA site Ancestry to study the genetics of longevity.
"None of these ideas are unique," Otte said. "And none of them are practical."
Companies like 23andMe look at genetic mutations that raise the risk of developing cancer. 23andMe's health test, for example, provides a glimpse at some of the well-known mutations tied to breast cancer.
A related but separate concept involves studying the genetics of cancer tumors.
Freenome, Otte's company, uses a blood test to look at the DNA inside cancer tumors. The goal is to reveal new targets for the next generation of cancer treatments.
Epstein appeared not to understand the distinction between the two.
"What he is describing is not within the realm of possibilities today, and probably not for at least 500 years. It's clear that he didn't have a deep understanding of any of the science behind this," Otte said.
Epstein seemingly knew that his ideas sounded far-fetched. At one point during the testimony, he told the commissioners, "I am not a mad man."
While discussing the science that his new venture would involve, Epstein rambled, sometimes exploring tangents that appeared unrelated to the project.
When asked how the setup might work, he answered: "It's the Frankenstein version but it's true, yes. In fact it will turn out that certain people can learn certain things. Certain people can move through space differently."
Epstein also compared St. Thomas to Iceland and said the island was an ideal location for DNA analysis because of its isolation.
"Places, frankly, like St. Thomas are the perfect place to sequence people because it's so isolated. You are able to get much better data than ever before," he said.
But experts told Business Insider that St. Thomas' complex history, punctured with waves of immigration from the slave trade, meant that it was essentially the opposite of isolated…
In 2003, Epstein gave $6.5 million dollars to Harvard to start a new academic track called the Program for Evolutionary Dynamics. It was led by Nowak, and in 2012, his researchers developed the first mathematical model showing how colon cancer cells stop responding to a type of cancer treatment, the Wall Street Journal reported.
To start his DNA sequencing project in St. Thomas, Otte believes Epstein aimed to sequence the genes of the local community.
"I get the sense that he believed the US Virgin Islands was likely to have looser guidelines around patient health data," Otte said.
https://www.businessinsider.com/jeffrey-epstein-dna-genetics-research-drug-companies-2019-8